Search Results - "Journal of Psychopharmacology"

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial by Griffiths, Roland R, Johnson, Matthew W, Carducci, Michael A, Umbricht, Annie, Richards, William A, Richards, Brian D, Cosimano, Mary P, Klinedinst, Margaret A

“…Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease…”
Get full text

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial by Ross, Stephen, Bossis, Anthony, Guss, Jeffrey, Agin-Liebes, Gabrielle, Malone, Tara, Cohen, Barry, Mennenga, Sarah E, Belser, Alexander, Kalliontzi, Krystallia, Babb, James, Su, Zhe, Corby, Patricia, Schmidt, Brian L

“…Background: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes…”
Get full text

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up by Gukasyan, Natalie, Davis, Alan K, Barrett, Frederick S, Cosimano, Mary P, Sepeda, Nathan D, Johnson, Matthew W, Griffiths, Roland R

“…Background: Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive…”
Get full text

Serotonin and brain function: a tale of two receptors by Carhart-Harris, RL, Nutt, DJ

“…Previous attempts to identify a unified theory of brain serotonin function have largely failed to achieve consensus. In this present synthesis, we integrate…”
Get full text

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology by Goodwin, GM, Haddad, PM, Ferrier, IN, Aronson, JK, Barnes, TRH, Cipriani, A, Coghill, DR, Fazel, S, Geddes, JR, Grunze, H, Holmes, EA, Howes, O, Hudson, S, Hunt, N, Jones, I, Macmillan, IC, McAllister-Williams, H, Miklowitz, DR, Morriss, R, Munafò, M, Paton, C, Sahakian, BJ, Saunders, KEA, Sinclair, JMA, Taylor, D, Vieta, E, Young, AH

“…The British Association for Psychopharmacology guidelines specify the scope and targets of treatment for bipolar disorder. The third version is based…”
Get full text

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology by Barnes, Thomas RE, Drake, Richard, Paton, Carol, Cooper, Stephen J, Deakin, Bill, Ferrier, I Nicol, Gregory, Catherine J, Haddad, Peter M, Howes, Oliver D, Jones, Ian, Joyce, Eileen M, Lewis, Shôn, Lingford-Hughes, Anne, MacCabe, James H, Owens, David Cunningham, Patel, Maxine X, Sinclair, Julia MA, Stone, James M, Talbot, Peter S, Upthegrove, Rachel, Wieck, Angelika, Yung, Alison R

“…These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011. They address the scope and targets…”
Get full text

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors by Griffiths, Roland R, Johnson, Matthew W, Richards, William A, Richards, Brian D, Jesse, Robert, MacLean, Katherine A, Barrett, Frederick S, Cosimano, Mary P, Klinedinst, Maggie A

“…Psilocybin can occasion mystical-type experiences with participant-attributed increases in well-being. However, little research has examined enduring changes…”
Get full text

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science by Schlag, Anne K, Aday, Jacob, Salam, Iram, Neill, Jo C, Nutt, David J

“…Background: Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a…”
Get full text

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines by Cleare, Anthony, Pariante, CM, Young, AH, Anderson, IM, Christmas, D, Cowen, PJ, Dickens, C, Ferrier, IN, Geddes, J, Gilbody, S, Haddad, PM, Katona, C, Lewis, G, Malizia, A, McAllister-Williams, RH, Ramchandani, P, Scott, J, Taylor, D, Uher, R

“…A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was…”
Get full text

Psychedelics and the essential importance of context by Carhart-Harris, Robin L, Roseman, Leor, Haijen, Eline, Erritzoe, David, Watts, Rosalind, Branchi, Igor, Kaelen, Mendel

“…Psychedelic drugs are making waves as modern trials support their therapeutic potential and various media continue to pique public interest. In this opinion…”
Get full text

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update by Wilson, Sue, Anderson, Kirstie, Baldwin, David, Dijk, Derk-Jan, Espie, Audrey, Espie, Colin, Gringras, Paul, Krystal, Andrew, Nutt, David, Selsick, Hugh, Sharpley, Ann

“…This British Association for Psychopharmacology guideline replaces the original version published in 2010, and contains updated information and…”
Get full text

Glutamate and dopamine in schizophrenia: An update for the 21st century by Howes, Oliver, McCutcheon, Rob, Stone, James

“…The glutamate and dopamine hypotheses are leading theories of the pathoaetiology of schizophrenia. Both were initially based on indirect evidence from…”
Get full text

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction by Johnson, Matthew W, Garcia-Romeu, Albert, Cosimano, Mary P, Griffiths, Roland R

“…Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been…”
Get full text

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences by Carbonaro, Theresa M, Bradstreet, Matthew P, Barrett, Frederick S, MacLean, Katherine A, Jesse, Robert, Johnson, Matthew W, Griffiths, Roland R

“…Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean…”
Get full text

Ketamine: A tale of two enantiomers by Jelen, Luke A, Young, Allan H, Stone, James M

“…The discovery of the rapid antidepressant effects of the dissociative anaesthetic ketamine, an uncompetitive N-Methyl-D-Aspartate receptor antagonist, is…”
Get full text

Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology by Hartogsohn, Ido

“…Placebo response theory and set and setting theory are two fields which examine how non-biological factors shape the response to therapy. Both consider factors…”
Get full text

Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology by Howes, Oliver D, Rogdaki, Maria, Findon, James L, Wichers, Robert H, Charman, Tony, King, Bryan H, Loth, Eva, McAlonan, Gráinne M, McCracken, James T, Parr, Jeremy R, Povey, Carol, Santosh, Paramala, Wallace, Simon, Simonoff, Emily, Murphy, Declan G

“…An expert review of the aetiology, assessment, and treatment of autism spectrum disorder, and recommendations for diagnosis, management and service provision…”
Get full text

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer by Agin-Liebes, Gabrielle I, Malone, Tara, Yalch, Matthew M, Mennenga, Sarah E, Ponté, K Linnae, Guss, Jeffrey, Bossis, Anthony P, Grigsby, Jim, Fischer, Stacy, Ross, Stephen

“…Background: A recently published randomized controlled trial compared single-dose psilocybin with single-dose niacin in conjunction with psychotherapy in…”
Get full text

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin by Barrett, Frederick S, Johnson, Matthew W, Griffiths, Roland R

“…The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by…”
Get full text

Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy by Kopschina Feltes, Paula, Doorduin, Janine, Klein, Hans C, Juárez-Orozco, Luis Eduardo, Dierckx, Rudi AJO, Moriguchi-Jeckel, Cristina M, de Vries, Erik FJ

“…Major depressive disorder (MDD) is a prevalent and disabling psychiatric disease with rates of non-responsiveness to antidepressants ranging from 30–50%…”
Get full text